This Award Notice opportunity from Department Of Defense was posted on August 24, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
INSULIN HUMAN INJEC
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The Defense Logistics Agency awarded contract SPE2DP24F2642 to DMS Pharmaceutical Group Inc on August 24, 2026. This award serves as a delivery order under the primary contract SPE2DX15D9383 and is specifically for the procurement of human insulin injections, identified by national stock number 6505012154825. The contract is managed by the Department of Defense and was posted via the DIBBS platform. While the total contract price is detailed within the award documentation, the agreement establishes the supply of critical pharmaceutical materials to the federal government.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
2AI Contract Breakdown
Uniform Contract FormatContract not broken down yet
CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.
Timeline
Organization & Contact Information
Full Description
More opportunities from Department Of Defense → Defense Logistics Agency
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
